Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internat…
Biotechnology
US, Novato [HQ]
Ratios
13 Sheets · Starting from 2023Margins, Growth Rates In %
| Ratio | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||
| Gross Margin | - - | - - | - - | - - | - - | 100.00 | 99.96 | 97.77 | 91.31 | 97.74 | 95.44 | 92.21 | 89.59 | |
| Profit Margin | - - | - - | - - | - - | - - | -184,867.67 | -11,567.34 | -383.75 | -388.31 | -68.84 | -129.20 | -194.71 | -139.70 | |
| Operating Margin | - - | - - | - - | - - | - - | -186,471.43 | -12,593.49 | -721.18 | -408.98 | -121.80 | -108.63 | -178.60 | -131.08 | |
|
EPS Growth
|
- - | -136.67 | -70.42 | -71.90 | -90.39 | -56.82 | -14.65 | 44.24 | -79.35 | 56.88 | -118.24 | -51.05 | 18.48 | |
| EPS USD | -30.00 | -71.00 | -121.00 | -208.00 | -396.00 | -621.00 | -712.00 | -397.00 | -712.00 | -307.00 | -670.00 | -1,012.00 | -825.00 | |
| Return on Assets (ROA) | -56.47 | -18.49 | -58.79 | -30.21 | -26.02 | -45.48 | -61.57 | -27.46 | -35.47 | -10.60 | -29.82 | -45.77 | -40.69 | |
| Return on Equity (ROE) | -64.35 | -19.37 | -69.99 | -32.34 | -27.42 | -51.87 | -78.79 | -32.45 | -61.60 | -16.16 | -49.21 | -200.69 | -220.26 | |
| Return on Invested Capital (ROIC) | -63.88 | -18.55 | -58.90 | -30.35 | -27.37 | -52.33 | -81.42 | -61.15 | -61.91 | -27.63 | -39.67 | -170.32 | -178.13 | |
| Solvency | ||||||||||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | - - | - - | - - | - - | - - | - - | - - | - - | 3.26 | 2.74 | 2.76 | 2.04 | 2.90 | |
| Debt/Equity | - - | - - | - - | - - | - - | - - | - - | - - | 5.66 | 4.18 | 4.55 | 8.96 | 15.67 | |
| Debt/EBITDA | 162.64 | 537.98 | 21.45 | 42.84 | 63.93 | 64.97 | 30.55 | 20.94 | 96.33 | 206.31 | 69.62 | 15.85 | 32.97 | |
|
Debt/Capitalization
|
- - | - - | - - | - - | - - | - - | - - | - - | 5.36 | 4.01 | 4.35 | 8.23 | 13.55 | |
| Long-Term Debt/Capitalization | - - | - - | - - | - - | - - | - - | - - | - - | 4.35 | 3.29 | 3.24 | 5.32 | 9.99 | |
| Interest Debt per Share USD | 0.01 | - - | - - | - - | - - | - - | - - | - - | 0.67 | 1.34 | 1.05 | 1.07 | 1.48 | |
| Debt Growth | - - | - - | - - | - - | - - | - - | - - | - - | - - | 30.37 | -12.97 | -24.73 | 36.64 | |
| Liquidity | ||||||||||||||
| Current Ratio | 1,096.40 | 2,711.57 | 932.70 | 1,497.86 | 1,612.60 | 826.62 | 344.25 | 699.06 | 823.83 | 683.14 | 472.30 | 338.39 | 261.09 | |
| Quick Ratio | 1,075.88 | 2,703.58 | 901.49 | 1,497.86 | 1,565.29 | 630.86 | 337.49 | 632.25 | 762.90 | 645.87 | 423.79 | 301.75 | 231.99 | |
| Cash Ratio | 1,065.57 | 2,703.58 | 125.43 | 194.33 | 335.16 | 267.38 | 141.50 | 151.80 | 419.73 | 376.31 | 169.59 | 50.90 | 76.16 | |
| Operating Cash Flow Ratio | -500 | -300 | -500 | -300 | -300 | -200 | -300 | -300 | -300 | - - | -100 | -100 | -100 | |
| Turnover | ||||||||||||||
| Inventory Turnover | - - | - - | - - | - - | - - | - - | 0.13 | 16.22 | 78.02 | 46.97 | 98.63 | 105.81 | 133.09 | |
| Receivables Turnover | - - | - - | - - | - - | - - | - - | 50.50 | 404.20 | 315.78 | 1,173.65 | 1,235.95 | 898.33 | 591.70 | |
| Payables Turnover | - - | - - | - - | - - | - - | - - | 0.01 | 9.34 | 69.99 | 47.43 | 93.41 | 65.44 | 107.35 | |
|
Asset Turnover
|
- - | - - | - - | - - | - - | 0.02 | 0.53 | 7.16 | 9.13 | 15.40 | 23.08 | 23.51 | 29.12 | |
| Fixed Turnover | - - | - - | - - | - - | - - | 0.78 | 11.96 | 256.88 | 138.89 | 237.66 | 199.46 | 127.18 | 149.45 | |
| Coverage | ||||||||||||||
| Interest Coverage | -2,430.00 | - - | - - | - - | - - | - - | - - | - - | -37,372.07 | -991.61 | -1,297.45 | -1,508.59 | -862.38 | |
| Asset Coverage | - - | - - | - - | - - | - - | - - | - - | - - | 2,400 | 3,000 | 2,900 | 3,500 | 2,400 | |
| Cash Flow Coverage (CFGR) | - - | - - | - - | - - | - - | - - | - - | - - | -933.67 | -274.16 | -806.99 | -1,204.27 | -1,099.88 | |
| EBITDA Coverage | -2,400 | - - | - - | - - | - - | - - | - - | - - | -36,200 | -900 | -1,200 | -1,400 | -700 | |
| Dividend Coverage | - - | - - | - - | 1,300 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Market Prospects | ||||||||||||||
| Dividend Yield | - - | - - | - - | 0.34 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -0.70 | -1.68 | -2.86 | -4.74 | -3.53 | -8.83 | -15.35 | -9.13 | -16.67 | -2.22 | -7.96 | -21.84 | -17.25 | |
|
Price/Earnings (P/E)
|
-14,226.96 | -5,965.50 | -3,501.18 | -2,109.97 | -2,833.63 | -1,132.03 | -651.68 | -1,095.20 | -600.01 | -4,514.68 | -1,255.64 | -457.88 | -579.73 | |
| Price/Earnings Growth (PEG) | - - | -43.65 | -49.72 | -29.35 | -31.35 | -19.92 | -44.47 | 24.75 | -7.56 | 79.37 | -10.62 | -8.97 | 31.37 | |
|
Price/Book (P/B)
|
9,155.35 | 1,155.33 | 2,450.39 | 682.26 | 776.94 | 587.24 | 513.48 | 355.43 | 369.61 | 729.65 | 617.95 | 918.92 | 1,276.94 | |
| Price/Tangible Book (P/TB) | 9,155.35 | 1,155.33 | 2,450.39 | 682.26 | 776.94 | 587.24 | 513.48 | 355.43 | 369.61 | 729.65 | 617.95 | 918.92 | 1,276.94 | |
| Price/Sales (P/S) | - - | - - | - - | - - | - - | 2,092,748.50 | 75,381.94 | 4,202.79 | 2,329.87 | 3,107.72 | 1,622.32 | 891.51 | 809.87 | |
|
Price/Cash Flow (P/CF)
|
-16,727.97 | -7,792.74 | -3,935.46 | -2,827.00 | -3,893.55 | -1,729.06 | -775.67 | -744.83 | -699.63 | -6,370.33 | -1,683.20 | -851.36 | -740.70 | |
| Price/Free CF (P/FCF) | -15,289.57 | -7,167.37 | -3,884.79 | -2,697.14 | -3,719.64 | -1,626.14 | -767.23 | -734.53 | -652.70 | -4,782.31 | -1,384.43 | -615.12 | -674.28 | |
| Price/Operating CF (P/OCF) | -16,727.97 | -7,792.74 | -3,935.46 | -2,827.00 | -3,893.55 | -1,729.06 | -775.67 | -744.83 | -699.63 | -6,370.33 | -1,683.20 | -851.36 | -740.70 |